Skip to Content
Merck
CN

HPLC Analysis of Atorvastatin and Related Compound E on Kromasil® 5-AmyCoat Chiral

HPLC Analysis of Atorvastatin and Related Compound E on Kromasil® 5-AmyCoat Chiral application for HPLC

Materials

mobile phase component

Product No.
Description
Pricing

Trifluoroacetic acid

≥99%, for protein sequencing

Hexane

puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99% (GC)

Ethyl alcohol, Pure

200 proof, HPLC/spectrophotometric grade

CONDITIONS

column

Kromasil 5-AmyCoat, 25 cm x 4.6 mm, 5 μm particles (K08670348)

mobile phase

84:16 hexane: ethanol with 0.1% TFA

flow rate

1 mL/min

pressure

1117 psi (77 bar)

column temp.

25 °C

detector

UV, 254 nm

injection

20 μL

sample

50 μg/mL atorva

Description

Analysis Note

Atorvastatin calcium also known as HMG-CoA reductase inhibitors in a class of lipid-lowering medications that reduces levels of “bad” cholesterol (low-density lipoprotein, or LDL) and triglycerides in the blood and raise “good” cholesterol (high-density lipoprotein, or HDL). The enantiomer of atorvastatin (related compound E) could qualitatively and quantitatively differ in their activities, in pharmacokinetic behavior or pharmacodynamics. The application exhibits baseline resolution under 9 minutes of a racemic mixture of atorvastatin calcium and related compound E on a 5.0 μm Kromasil 5-AmyCoat Chiral.

Legal Information

Kromasil is a registered trademark of EKA Chemicals AB